StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q2 2026
588
Period ended Jun 30, 2026
Change on a year earlier
+75.0%
336 in Q2 2025
History
13 quarters
Since Q2 2023
Sources
5
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWinrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026588+75.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026525+87.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025467+133.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025360+80.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025336+125.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025280+300.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024200–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024200–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 2024149–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202470–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 20230–Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-05) ↗

Breakdown

What makes up winrevair (sotatercept — pah activin signaling inhibitor, launched q2 2024) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — Worldwide sales ($M) ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_winrevair

See every metric in the Merck KPI table. Data updated Oct 26, 2026.